RxDoctor Payments Data

J D Brandman

Psychiatric/Mental Health · Honolulu, HINPI 1336100049

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $49,537 of the $63,363 with a category attached, or 78.2%. 14 manufacturers reported payments, led by AbbVie at 49.1% of the total. Reporting peaked in 2023 at $19,028 and has fallen 54.0% since, to $8,750 in 2025. Among psychiatric/mental health clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$63,363in general payments, 2019–2025

Across 246 payments — averaging $257.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$31K
  • Otsuka America Pharmaceutical, Inc.$16K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$8K
  • Teva Pharmaceuticals USA, Inc.$5K
  • Neurocrine Biosciences, Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$504
  • plus $1K from 8 others

What the payments were for

  • Speaking & faculty fees$49,53778%
  • Travel & lodging$2,3444%
  • Food & beverage$11,41518%
  • Education$670%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,363 in reported general payments places this provider in the 95th percentile of 103 psychiatric/mental health providers in Hawaii.

See all psychiatric/mental health providers in Hawaii

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl64$101,363
RexultiBrexpiprazole15$18,879
Asenapine Maleate20$3,489
Lamotrigine156$1,814
Aripiprazole20$1,294
Trazodone Hcl59$688
Propranolol Hcl27$426
Clonazepam47$348
Quetiapine Fumarate26$286
Prazosin Hcl18$247
Hydroxyzine Hcl15$229
Citalopram HbrCitalopram Hydrobromide12$120
Escitalopram Oxalate13$47
Alprazolam14$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$31,089$101,36364 claims
Otsuka America Pharmaceutical, Inc.Rexulti$15,587$18,87915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 103 psychiatric/mental health providers in Hawaii.

Other psychiatric/mental health in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →